Rigel Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: RIGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rigel Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Rigel Pharmaceuticals generated $30.7 million of operating cash flow. That left free cash flow of $30.7 million, a free-cash-flow margin of 38.9% of revenue. Free cash flow was up 0.4% from the prior year's $30.5 million.
Rigel Pharmaceuticals returned $511,000 to shareholders through share repurchases, equal to 2% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Rigel Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 17.29M | 8.65M | 268.06M | 27.90M | 59.61M | 11.45M | 14.34M | 12.42M | -1.03M | -8.25M | 737.00K | -5.69M |
| Net Income growth (YoY) | -71.00% | -24.39% | +1769.22% | +124.62% | — | — | +1845.86% | — | — | — | -47.39% | — |
| Depreciation & Amortization | 848.00K | 597.00K | 601.00K | 603.00K | 607.00K | 604.00K | 604.00K | 611.00K | 613.00K | 400.00K | 293.00K | 292.00K |
| Stock-Based Compensation | 6.84M | 3.46M | 2.75M | 3.36M | 3.28M | 3.32M | 2.09M | 2.64M | 2.53M | 5.13M | 1.93M | 1.94M |
| Change in Working Capital | -3.86M | -5.26M | -4.75M | -11.15M | 3.17M | -11.05M | -9.55M | -2.04M | -6.24M | 278.00K | -9.77M | 33.00K |
| Operating Cash Flow | 30.65M | 2.73M | 21.98M | 24.03M | 30.54M | -893.00K | 14.50M | 21.68M | 302.00K | -5.01M | -6.24M | -1.36M |
| Investing Cash Flow | 17.45M | -7.97M | -25.36M | -33.17M | -23.28M | -10.55M | -10.91M | 3.80M | 10.93M | 313.00K | -6.87M | -1.17M |
| Share Repurchases | -511.00K | -3.74M | — | — | 0 | 0 | — | — | — | — | — | — |
| Financing Cash Flow | -11.70M | -10.92M | -4.57M | 4.27M | 418.00K | 484.00K | 1.47M | -9.84M | -752.00K | -2.51M | 486.00K | -869.00K |
| Net Change in Cash | 36.41M | -16.17M | -7.95M | -4.87M | 7.68M | -10.96M | 5.05M | 15.64M | 10.48M | -7.21M | -12.63M | -3.40M |
| Free Cash Flow | 30.65M | 2.73M | 21.98M | 24.03M | 30.54M | -893.00K | 14.50M | 21.68M | 302.00K | -5.01M | -6.24M | -1.36M |
This table shows 12 quarterly periods of Rigel Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RIGL's reporting calendar. What is a cash flow statement?